QuilA® adjuvanted Coxevac® sustains Th1-CD8⁺-type immunity and increases protection in Coxiella burnetii-challenged goats.

ABSTRACT: Coxevac® is the EMA-approved veterinary vaccine for the protection of cattle and goats against Q fever, a zoonotic bacterial disease due to Coxiella burnetii. Since Coxevac® reduces bacterial shedding and clinical symptoms but does not prevent infection, novel, ready-to-use vaccine formulations are needed to increase its immunogenicity. Here, a goat vaccination-challenge model was used to evaluate the impact of the commercially available saponin-based QuilA® adjuvant on Coxevac® immunity. Upon challenge, the QuilA®-Coxevac® group showed a stronger immune response reflected in a higher magnitude of total IgG and an increase in circulating and splenic CD8⁺ T-cells compared to the Coxevac® and challenged-control groups. The QuilA®-Coxevac® group was characterized by a targeted Th1-

SUBMITTER: Tomaiuolo S 

PROVIDER: S-EPMC9929268 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature